Regeneron Pharmaceuticals, Inc.
STABILIZED FORMULATIONS CONTAINING ANTI-PCSK9 ANTIBODIES
Last updated:
Abstract:
The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
Status:
Application
Type:
Utility
Filling date:
16 Jul 2020
Issue date:
25 Feb 2021